Article

GRF receives landmark gift

The Melza M. and Frank Theodore Barr Foundation has given $1.6 million to the Glaucoma Research Foundation.

San Francisco-The Melza M. and Frank Theodore Barr Foundation has given $1.6 million to the Glaucoma Research Foundation (GRF).

The donation, the largest single gift in the GRF’s 32-year history, according to the organization, will support the ongoing research of the Catalyst For a Cure consortium aimed at discovering a cure for glaucoma.

“The Barrs have been very generous in their support of glaucoma research, and their gift will have a major impact on the effort to find new treatments and eventually a cure for glaucoma,” said Thomas M. Brunner, GRF president and chief executive officer.

The Catalyst For a Cure research consortium, now in its ninth year, was formed with the goal of real-time collaboration to speed the process of discovery. Four principal scientists at four universities brought their experience in neuroscience, genetics, molecular biology, and vision to the effort. The principal scientists include Monica Vetter, PhD, University of Utah, Salt Lake City; Nick Marsh-Armstrong, PhD, Johns Hopkins University, Baltimore; Phil Horner, PhD, University of Washington, Seattle; and David Calkins, PhD, Vanderbilt University, Nashville, TN.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.